Norris Medicines Ltd Stock Price Today (NSE: NORRIS)
Fundamental Score
Norris Medicines Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Norris Medicines Ltd share price today is ₹13.35, down 1.70% on NSE/BSE as of 30 March 2026. Norris Medicines Ltd (NORRIS) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of ₹14.52 (Cr). The 52-week high for NORRIS share price is ₹22.10 and the 52-week low is ₹12.00.
Norris Medicines Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Norris Medicines Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Norris Medicines Share Price Analysis: A Value Investor's Perspective
The trading and distribution sector, particularly in the pharmaceutical niche, often sees inflated valuations based on potential rather than proven performance. This makes a conservative value investor particularly cautious. This analysis examines the current state of Norris Medicines share price of ₹14.75, focusing on factors critical to capital safety. Our primary concern is the company's ability to generate sustainable returns and build a resilient business.
One immediate red flag is the absence of a Price-to-Earnings (PE) ratio, indicating a lack of profitability. Furthermore, the Return on Capital Employed (ROCE) of -10.13% is deeply concerning. ROCE measures how efficiently a company is using its capital to generate profits. A negative ROCE suggests the company is destroying value rather than creating it. This dramatically impacts any potential "moat," as a company consistently losing money on its investments will struggle to maintain a competitive advantage.
When compared to sector peers, the situation warrants further scrutiny. Consider
Prismx Global Ventures Ltd; even if similar in size, a qualitative assessment of management quality is crucial. Are the management teams of companies like Prismx Global Ventures demonstrating better capital allocation skills and strategic execution compared to Norris Medicines Ltd? This can heavily impact future returns. Qualitative factors such as management experience, track record, and strategic vision are often overlooked but are vital for long-term value creation.The current financial data suggests Norris Medicines Ltd. faces significant challenges. The negative ROCE signals operational inefficiencies and a potential lack of competitive advantages. This necessitates a deep dive into the underlying causes – excessive debt, poor cost controls, or weak product offerings. Value investors prioritize capital preservation, and a company demonstrating such weak financial metrics demands considerable caution. This analysis forms a part of a comprehensive 80-parameter fundamental audit, rigorously verified by financial analyst Sweta Mishra, ensuring a thorough and objective evaluation of the company's financial health. It is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Norris Medicines Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NORRIS across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Revenue Growth (57.48%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Suboptimal ROCE (-10.13%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-3.20%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-5.78% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-2.02x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Norris Medicines Ltd Financial Statements
Comprehensive financial data for Norris Medicines Ltd including income statement, balance sheet and cash flow
About NORRIS (Norris Medicines Ltd)
Norris Medicines Ltd is a dynamic trading and distribution company specializing in the procurement and delivery of a broad spectrum of pharmaceutical products and healthcare soluti...ons. Operating within the complex Indian pharmaceutical landscape, Norris acts as a critical link connecting manufacturers with a vast network of retailers, hospitals, and healthcare providers. The company meticulously manages its supply chain, ensuring timely and efficient distribution of essential medicines and healthcare products across diverse geographical regions. Norris is dedicated to maintaining the highest standards of quality and compliance, meticulously adhering to regulatory guidelines and industry best practices to safeguard the integrity of the products they handle. Norris Medicines Ltd distinguishes itself through its comprehensive portfolio of traded and distributed products, catering to a wide range of therapeutic areas. These include, but are not limited to, essential medications for common ailments, specialized treatments for chronic conditions, and various healthcare supplies designed to enhance patient well-being. Beyond simply moving products, Norris focuses on building strong relationships with both its suppliers and its customers, fostering trust and collaboration. They actively monitor market trends and patient needs, enabling them to adapt their offerings and ensure that healthcare professionals have access to the medications and tools they require to provide optimal care. Norris Medicines Ltd is committed to facilitating access to quality healthcare solutions throughout India. By strategically managing logistics, maintaining stringent quality control measures, and fostering collaborative partnerships, the company plays a vital role in the healthcare ecosystem. With a focus on reliability and efficiency, Norris strives to be a trusted partner for both manufacturers and healthcare providers, contributing to improved patient outcomes and a healthier community. They are driven by a commitment to ethical business practices and a dedication to supporting the evolving needs of the Indian healthcare sector.
Company Details
Key Leadership
Latest News
NORRIS Share Price: Frequently Asked Questions
What is the current share price of Norris Medicines Ltd (NORRIS)?
As of 30 Mar 2026, 12:06 pm IST, Norris Medicines Ltd share price is ₹13.35. The NORRIS stock has a market capitalisation of ₹14.52 (Cr) on NSE/BSE.
Is NORRIS share price Overvalued or Undervalued?
NORRIS share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 35.45x. Based on this relative valuation, the Norris Medicines Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of NORRIS share price?
The 52-week high of NORRIS share price is ₹22.10 and the 52-week low is ₹12.00. These values are updated daily from NSE/BSE price data.
What factors affect the Norris Medicines Ltd share price?
Key factors influencing NORRIS share price include quarterly earnings growth (Sales Growth: 57.48%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Norris Medicines Ltd a good stock for long-term investment?
Norris Medicines Ltd shows a 5-year Profit Growth of 9.35% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in NORRIS shares.
How does Norris Medicines Ltd compare with its industry peers?
Norris Medicines Ltd competes with major peers in the Trading & Distributors. Investors should compare NORRIS share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of NORRIS and what does it mean?
NORRIS share price has a P/E ratio of N/Ax compared to the industry average of 35.45x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is NORRIS performing according to Bull Run's analysis?
NORRIS has a Bull Run fundamental score of 14/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NORRIS belong to?
NORRIS operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Norris Medicines Ltd share price.
What is Return on Equity (ROE) and why is it important for NORRIS?
NORRIS has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Norris Medicines Ltd generates profits from shareholders capital.
How is NORRIS debt-to-equity ratio and what does it indicate?
NORRIS has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is NORRIS dividend yield and is it a good dividend stock?
NORRIS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Norris Medicines Ltd shares.
How has NORRIS share price grown over the past 5 years?
NORRIS has achieved 5-year growth rates of: Sales Growth -5.78%, Profit Growth 9.35%, and EPS Growth 9.35%.
What is the promoter holding in NORRIS and why does it matter?
Promoters hold 34.00% of NORRIS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Norris Medicines Ltd.
What is NORRIS market capitalisation category?
NORRIS has a market capitalisation of ₹15 crores, placing it in the Small-cap category.
How volatile is NORRIS stock?
NORRIS has a beta of N/A. A beta > 1 suggests the Norris Medicines Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NORRIS operating profit margin trend?
NORRIS has a 5-year average Operating Profit Margin (OPM) of -3.20%, indicating the company's operational efficiency.
How is NORRIS quarterly performance?
Recent quarterly performance shows Norris Medicines Ltd YoY Sales Growth of 57.48% and YoY Profit Growth of -100.00%.
What is the institutional holding pattern in NORRIS?
NORRIS has FII holding of 0.00% and DII holding of 0.07%. Significant institutional holding often suggests professional confidence in the Norris Medicines Ltd stock.